SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.
| Status: | Completed |
|---|---|
| Conditions: | Alzheimer Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 55 - 85 |
| Updated: | 10/14/2017 |
| Start Date: | February 2014 |
| End Date: | September 2016 |
A Randomised, Double-Blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI1814 in Subjects With Mild to Moderate Alzheimer's Disease.
The purpose of this study is to assess the safety, drug levels and effects on the body of 1
or 3 injections of MEDI1814, in people with mild to moderate Alzhiemer's Disease or healthy
elderly people.
or 3 injections of MEDI1814, in people with mild to moderate Alzhiemer's Disease or healthy
elderly people.
Inclusion Criteria Male and female (non child bearing potential) subjects Mild-moderate
Alzheimer's Disease
Exclusion Criteria History or evidence of significant autoimmune disease Presence of
psychiatric disorder which would affect completion of the study Current serious or unstable
clinically important illness
We found this trial at
10
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials